While 20% of neuroblastomas harbor MYCN amplifications, directly classifying them as high-risk, around 50% of high-risk tumors lack MYCN amplification and display molecular diversity within the high-risk tumor group [1, 4]. The gene discussed is MYCN; the disease is neoplasm.